Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic regulation of profibrotic macrophages in systemic sclerosis- associated interstitial lung disease

ABSTRACT: Epigenetic regulation of profibrotic macrophages in systemic sclerosis- associated interstitial lung disease

PROVIDER: PRJNA874032 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Epigenetic regulation of profibrotic macrophages in systemic sclerosis- associated interstitial lung disease

Project description:Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of death in patients with systemic sclerosis (SSc) with unclear pathogenesis and limited treatment options. Evidence strongly supports an important role for profibrotic, SPP1-expressing macrophages in SSc-ILD. We sought to define the transcriptome and chromatin structural changes of SPP1 SSc-ILD macrophages, so as to better understand their role in promoting fibrosis and to identify transcription factors associated with open chromatin driving their altered phenotype.

2022-09-02 | GSE212109 | GEO

Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis

Project description:We identified eighty two skin transcripts significantly correlated with the severity of interstitial lung disease (ILD) in systemic sclerosis. These genes separated patients with more sever ILD in unsupervised hierarchical clustering. Pathway analysis revealed pathways involved in extravasation and adhesion of inflammatory cells to endothelium. Skin biopsy samples from 59 patients enrolled in the GENISOS cohort or an open label imatinib study were examined by global gene expression studies.

2013-07-12 | E-GEOD-47162 | biostudies-arrayexpress

Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis

2013-07-12 | GSE47162 | GEO

Modulation of profibrotic pathways in systemic sclerosis skin from focuSSced trial with treatment

Project description:Modulation of profibrotic pathways in systemic sclerosis skin from focuSSced trial with treatment

| PRJNA967299 | ENA

Lung interstitial macrophages

Project description:Lung interstitial macrophages

| PRJNA798739 | ENA

Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease

Project description:Myofibroblasts are key effector cells in the extracellular matrix remodeling of systemic sclerosis-associated interstitial lung disease (SSc-ILD), however the diversity of fibroblast populations present in the healthy and SSc-ILD lung is unknown, and has prevented the specific study of the myofibroblast transcriptome. We sought to identify and define the transcriptomes of myofibroblasts and other mesenchymal cell populations in human healthy and SSc-ILD lungs to understand how alterations in fibroblast phenotypes lead to SSc-ILD fibrosis.

2019-08-14 | GSE128169 | GEO

Peripheral blood gene expression profiling predicts response to mycophenolate in systemic sclerosis related interstitial lung disease

Project description:PBC RNA samples from 134 baseline and 98 month-12 visits, corresponding to the active treatment period of both arms in Scleroderma Lung Study II, along with 45 healthy controls were investigated by global RNA sequencing. The objective was to examine the peripheral blood cell (PBC) gene expression changes ensuing from mycophenolate mofetil (MMF) or cyclophosphamide (CYC) treatment and to determine the predictive significance of baseline PBC transcript scores for response to immunosuppression in systemic sclerosis (SSc) related interstitial lung disease (ILD).

2022-02-01 | GSE181228 | GEO

Novel Pulmonary Imaging Biomarkers and Cutaneous Gene Expression Subsetting for Patient Selection and Outcome Assessment in the Dasatinib Treatment of Systemic Sclerosis-associated Interstitial Lung Disease

Project description:There are no effective treatments or clinical response markers for systemic sclerosis (SSc). We sought to assess the potential of novel imaging biomarkers and gene expression profiling approaches in a clinical trial of the tyrosine kinase inhibitor dasatinib in SSc patients with interstitial lung disease (SSc-ILD).

2018-02-13 | GSE79387 | GEO

Evaluation of common profibrotic pathway across interstitial lung disease

Project description:Evaluation of common profibrotic pathway across interstitial lung disease

| PRJNA967318 | ENA

Transcriptomic characterization of lung pericytes in systemic sclerosis associated interstitial lung disease (SSc-ILD)

Project description:Transcriptomic characterization of lung pericytes in systemic sclerosis associated interstitial lung disease (SSc-ILD)

| PRJNA922512 | ENA